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Congenital heart disease (CHD) accounts for nearly one-third of all major congenital anomalies. CHD birth prevalence
worldwide and over time is suggested to vary; however, a complete overview is missing. This systematic review in-
cluded 114 papers, comprising a total study population of 24,091,867 live births with CHD identified in 164,396 indi-
viduals. Birth prevalence of total CHD and the 8 most common subtypes were pooled in 5-year time periods since
1930 and in continent and income groups since 1970 using the inverse variance method. Reported total CHD birth
prevalence increased substantially over time, from 0.6 per 1,000 live births (95% confidence interval [CI]: 0.4 to 0.8)
in 1930 to 1934 to 9.1 per 1,000 live births (95% CI: 9.0 to 9.2) after 1995. Over the last 15 years, stabilization oc-
curred, corresponding to 1.35 million newborns with CHD every year. Significant geographical differences were found.
Asia reported the highest CHD birth prevalence, with 9.3 per 1,000 live births (95% CI: 8.9 to 9.7), with relatively
more pulmonary outflow obstructions and fewer left ventricular outflow tract obstructions. Reported total CHD birth
prevalence in Europe was significantly higher than in North America (8.2 per 1,000 live births [95% CI: 8.1 to 8.3] vs.
6.9 per 1,000 live births [95% CI: 6.7 to 7.1]; p  0.001). Access to health care is still limited in many parts of the
world, as are diagnostic facilities, probably accounting for differences in reported birth prevalence between high- and
low-income countries. Observed differences may also be of genetic, environmental, socioeconomical, or ethnic origin, and
there needs to be further investigation to tailor the management of this global health problem. (J Am Coll Cardiol
2011;58:2241–7) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.08.025Congenital heart disease (CHD) is the most common cause
of major congenital anomalies, representing a major global
health problem. Twenty-eight percent of all major congen-
ital anomalies consist of heart defects (1). Reported birth
prevalence of CHD varies widely among studies worldwide.
The estimate of 8 per 1,000 live births is generally accepted as
the best approximation (2). CHD, by definition, is present
from birth. The most practical measurement of CHD occur-
rence is birth prevalence per 1,000 live births (3).
Massive breakthroughs have been achieved in cardiovas-
cular diagnostics and cardiothoracic surgery over the past
century, leading to an increased survival of newborns with
CHD. Consequently, more patients with CHD reach
adulthood, creating a completely new and steadily growing
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accepted August 8, 2011.patient population: patients with grown-up congenital heart
disease (GUCH). The prevalence of CHD is estimated to
be 4 per 1,000 adults (4). Patients with GUCH often need
long-term expert medical care and healthcare-related costs
are high (5). Therefore, the global health burden as a result
of CHD increases quickly.
It is important to have reliable information about world-
wide CHD birth prevalence because this may lead to better
insight into its etiology. In addition, dedicated care could be
better planned and provided. Variation in CHD occurrences
over time and worldwide has been suggested, but a complete
overview is missing. In this systematic review and meta-
analysis, we provide a complete worldwide overview of the
reported birth prevalence of total CHD and the 8 most
common subtypes of CHD from 1930 until 2010.
Methods
Search strategy. We conducted a PubMed literature search on
September 23, 2010, using the following search terms: “heart
defects, congenital/epidemiology,” and “incidence” or “preva-
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original research papers with Eng-
lish abstracts. No time restriction
for publication dates was used. Re-
ports of large governmental birth
registries were searched online.
All titles and abstracts were
screened for study population
(live births, children), type of
CHD, and birth prevalence. Stud-
ies were eligible if they reported
the birth prevalence of total CHD
or 1 of the 8 most common CHD
subtypes: ventricular septal defect
(VSD), atrial septal defect (ASD),
pulmonary stenosis (PS), patent
ductus arteriosus (PDA), tetral-
ogy of Fallot (TOF), coarctation
(Coarc), transposition of the great
arteries (TGA), and aortic stenosis
(AoS). CHD was defined accord-
ing to the definition of Mitchell et al. (6); namely, “a gross
structural abnormality of the heart or intrathoracic great vessels
that is actually or potentially of functional significance.” This
definition excludes PDA in premature infants, Marfan syn-
drome, bicuspid aortic valve, mitral valve prolapse, cardiomy-
opathies, and congenital arrhythmias. Papers studying only
specific groups (e.g., only Down syndrome), rheumatic heart
disease, or case studies of rare defects were excluded. Papers
focusing on etiology, (pre-natal) diagnosis, treatment, progno-
sis, or animal research were also excluded.
After exclusion on the basis of the title and abstract, full
papers were carefully read and reconsidered according to all
abovementioned inclusion and exclusion criteria. Studies
focusing on CHD prevalence in schoolchildren age 5
ears or including only severe forms of CHD were excluded.
hen a study was eligible for inclusion, we verified the
enominator and numerator and recalculated the estimated
irth prevalence to check accuracy. Studies with incorrect or
issing denominators or numerator were excluded. Three
uthors performed the search independently using these
nclusion and exclusion criteria. In case of disagreement, an
greement was negotiated. References of selected papers
ere crosschecked with the same inclusion and exclusion
riteria.
ata extraction. Selected papers were reviewed and study
haracteristics were tabulated in a MS Excel for Windows
Microsoft Corporation, Redmond, Washington) and Re-
iew Manager version 5.0 (Review Manager, The Nordic
ochrane Centre, The Cochrane Collaboration, Copenha-
en, Denmark). The following study characteristics were
egistered: time period during which the study was per-
ormed, country, study design (retrospective or prospective),
ge of patients, diagnostic method, number of live births,
umber of patients with CHD, and birth prevalence of total
Abbreviations
and Acronyms
AoS  aortic stenosis
ASD  atrial septal defect
CHD  congenital heart
disease
CI  confidence interval
Coarc  coarctation of the
aorta
GUCH  grown-up
congenital heart disease
PDA  patent ductus
arteriosus
PS  pulmonary stenosis
TGA  transposition of the
great arteries
TOF  tetralogy of Fallot
VSD  ventricular septal
defectHD and 8 CHD subtypes. Studies were grouped accord-ng to 5-year time periods since 1930 to demonstrate time
rends. Time period is taken as the period in which the
tudy was performed. Before 1970, many differences in
vailability of diagnostic and registration facilities between
he continents existed, so we used only those studies
erformed after 1970 to compare continents and income
roups. World Bank Income groups based on gross national
ncome per capita in 2008 were defined as: low income
$975), lower-middle-income ($976 to $3,855), upper-
iddle-income ($3,856 to 11,905), and high income
$11,906) (7).
tatistical analysis. Statistical analyses were done in Re-
iew manager 5.0, MS Excel, and SPPS version 15.0 (SPSS,
hicago, Illinois). Birth prevalence of total CHD and the 8
ost common subtypes were pooled using the inverse
ariance method. Pooled group estimates were compared
ith a chi-square test. Time trends were plotted by using
he Savitzky-Golay smoothing technique. Heterogeneity on
asis of study design (retrospective vs. prospective), study
ize, continents, income groups and time periods was
xplored by using the Q and the I2 statistics and by means
of funnel plots.
Results
Search results. The systematic literature search yielded
1,136 potential eligible studies. After exclusion, cross-
referencing, and reaching agreement on 3 studies, 114
studies were included in this systematic literature review and
meta-analysis (Fig. 1, Online Table 1). This resulted in a
total study population of 24,091,867 live births with CHD
identified in 164,396 individuals. There were 12 reports of
prospective birth defect registries. Seventy-six studies used
echocardiography as the main diagnostic tool; the rest used
combinations of diagnostic tools, such as death certificates,
autopsy and surgical reports, physical examination, x-rays,
and catheterization.
Total CHD birth prevalence. Over time, the reported
total CHD birth prevalence increased substantially (Fig. 2),
from 0.6 per 1,000 live births (95% confidence interval [CI]:
0.4 to 0.8) in 1930 to 1934 to 9.1 per 1,000 live births (95%
CI: 9.0 to 9.2) after 1995. The increase over time was
S-shaped, with a first steep increase from 1930 to 1960,
followed by stabilization around 5.3 per 1,000 live births
from 1961 to 1975, a second steep increase from the late
1970s until 1995, and eventually stabilization around 9.1 per
1,000 live births in the last 15 years.
Significant geographical differences were found (Fig. 3A).
The highest reported total CHD birth prevalence was found
in Asia (9.3 per 1,000 live births [95% CI: 8.9 to 9.7]) and
the lowest in Africa (1.9 per 1,000 live births [95% CI: 1.1
to 3.5]). Reported total CHD birth prevalence in Asia was
significantly higher compared with all other continents (all,
p  0.001). Europe had the second highest reported total
CHD birth prevalence (8.2 per 1,000 live births [95% CI:
8.1 to 8.3]).
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groups were found (Fig. 3B), with the highest reported total
CHD birth prevalence in high-income countries (8.0 per
1,000 live births [95% CI: 7.9 to 8.1]; all, p  0.001).
Reported total CHD birth prevalence in upper- middle-
income countries was 7.3 per 1,000 live births (95% CI: 6.9
to 7.7) and 6.9 per 1,000 live births (95% CI: 6.1 to 7.7) in
lower-middle-income countries (p  0.013). No data from
low-income countries were available.
Birth prevalence of the 8 most common subtypes of
CHD. Reported birth prevalence of the 8 most common
CHD subtypes since 1945 is shown in Figure 4. Distribu-
tion of the 8 most common CHD subtypes worldwide is
shown with percentages in Figure 5. Worldwide reported
birth prevalence of the CHD subtypes (per 1,000 live births)
was: VSD, 2.62 (95% CI: 2.59 to 2.65); ASD, 1.64 (95%
CI: 1.61 to 1.67); PDA, 0.87 (95% CI: 0.83 to 0.91); PS,
0.50 (95% CI: 0.48 to 0.52); TOF, 0.34 (95% CI: 0.31 to
0.37); Coarc, 0.34 (95% CI: 0.32 to 0.36); TGA, 0.31 (95%
CI: 0.28 to 0.34); and AoS, 0.22 (95% CI: 0.20 to 0.24).
Significant geographical differences in reported birth
prevalence of the 8 most common CHD subtypes were
detected (Fig. 5). Asia reported relatively more pulmonary
outflow obstructions (PS and TOF) and fewer left ventric-
ular outflow tract obstructions (Coarc and AoS). Further-
more, Asia reported a lower TGA birth prevalence com-
pared with Europe, North America, South America, and
Oceania (p  0.001).
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Figure 1 Flow Chart of Study Selection
Flow chart representing the selection of studies during the systematic literature
search. Initial search yielded 1,136 potential eligible studies. After reading
titles and abstracts, 958 papers were excluded on the basis of exclusion crite-
ria named in the search strategy paragraph of the Methods section. Another
70 papers were excluded after evaluation of full text and recalculating denomi-
nators and nominators. Cross-referencing led to inclusion of 6 additional
papers, after which 114 papers were included in this systematic review.0
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Figure 2 Total CHD Birth Prevalence Over Time
Time course of reported total congenital heart disease (CHD) birth prevalence from 1930
and the squares represent the calculated birth prevalence values for each time period.
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Significant heterogeneity was observed within pooled estimates
for all time periods, continents and income groups (all I2
statistic  100%; Q statistic, p  0.001). Birth prevalence
estimates did not differ significantly between prospectively and
retrospectively designed studies or between large and small
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Figure 3 Total CHD Birth Prevalence per Continent and World B
(A) Reported total CHD birth prevalence per continent. *Reported total CHD birth
America (p  0.001), Oceania (p  0.001) and Africa (p  0.001). †Reported tot
North America (p 0 .001), South America (p  0.001), Oceania (p  0.001), and
group. ‡Reported total CHD birth prevalence in upper-middle income countries was sig
income countries. §Reported total CHD birth prevalence in high-income countries wasstudies. Funnel plots were symmetrical.Discussion
This meta-analysis is the first to systematically compile the
available published evidence on worldwide CHD birth
prevalence over the past century.
Changes over time in CHD birth prevalence. Over time,
a Asia Oceania Africa
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nce in Europe was significantly higher than in North America (p  0.001), South
birth prevalence in Asia was significantly higher than in Europe (p 0.001),
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live births in recent years. With a worldwide annual birth
rate around 150 million births (8), this corresponds to 1.35
million live births with CHD every year, representing a
major public health issue.
The increase in reported total CHD birth prevalence over
time may be caused by changes in diagnostic methods and
screening modalities rather than representing a true in-
crease. Over the past century, knowledge about diagnostics
and treatment of CHD increased considerably. Survival
increased dramatically due to improvements in the field of
cardiothoracic surgery and anesthesia. Specialized pediatric
cardiologists were trained, and large prospective birth defect
registries became available. Before the era of echocardiog-
raphy, detection of CHD was dependent on autopsy re-
ports, death certificates, physical examination, x-rays, cath-
eterization, and surgical reports. Therefore, only severely
affected subjects could be detected. In the 1970s, echocar-
diography was widely introduced into clinical practice,
making it possible to also diagnose asymptomatic patients as
well as patients with mild lesions (9). This development
probably explains the increased birth prevalence of total
CHD in the 1970s, as well as the increase in specific groups,
such as patients with VSD, ASD, and PDA. Furthermore,
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Figure 4 Birth Prevalence of CHD Subtypes Over Time
Time course of birth prevalence of the 8 most common CHD subtypes from 1945
PDA  patent ductus arteriosus; PS  pulmonary stenosis; TGA  transposition oechocardiography currently is often used as a screening toolbefore (noncardiac) surgery or full assessment in case of
noncardiac disease, causing an increase in diagnoses of minor
lesions such as a small VSD or ASD. Our results confirm
findings from the Metropolitan Atlanta Congenital Defects
Program that routine use of echocardiography has increased
diagnosis of minor defects (10). The relative stability of the
estimation of birth prevalence of complex CHD subtypes also
argues for a merely methodological increase.
Nonetheless, there are arguments that not only the
reported but also the true CHD birth prevalence changed
over time. Survival of premature infants has improved over
the last century, attributing to an increase in total CHD and
especially VSD birth prevalence (4). Because increasing
numbers of women in developed countries are delaying
childbearing to an older age, maternal age has increased in
the last decades, consequently causing a higher birth prev-
alence of congenital abnormalities (11,12). In addition, the
patient population with GUCH is steadily increasing and
their offspring is at increased risk of having a congenital
abnormality (13). Furthermore, one might hypothesize that
changes in environmental exposures—for example, due to
industrialization and urbanization—over the past century
have had effects on CHD birth prevalence. However, only
maternal pre-gestational diabetes mellitus, phenylketonuria,
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great arteries; TOF  tetralogy of Fallot; VSD  ventricular septal defect.98
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solvents have been proven to be associated with increased
risk of CHD (14). Exposure to ionizing radiation in
occupational settings or in clinical practice did not show any
associations with CHD birth prevalence (14). Data about
alcohol consumption, hard drugs, or cigarette smoking
during pregnancy are insufficient to determine risk for
CHD. The impact of increased use of fetal echocardiogra-
phy and pregnancy termination on reduction of CHD birth
prevalence is expected in the next time periods (15).
Furthermore, in the upcoming decades we will probably see
the effect of improving figures on infant survival and
socioeconomical circumstances in developing countries on
CHD birth prevalence.
Geographical and income group differences in CHD
birth prevalence. Important geographical differences were
found. Asia reported the highest total CHD birth preva-
lence (9.3 per 1,000 live births). This finding could in part
be attributed to high consanguinity rates in some study
populations (e.g., in Iran and India) (16,17). CHD birth
prevalence among children with consanguineous parents
was found to be considerably higher than in nonconsan-
guineous parents, suggesting an important genetic influence
(16). Very interesting is the relatively high birth prevalence
of pulmonary outflow tract obstructions (PS and TOF) and
low birth prevalence of left ventricular outflow tract obstruc-
tions (Coarc and AoS) in Asia. These findings confirm the
results of Jacobs et al. (18), who found that white children
seem to have more left ventricular obstructive lesions,
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Figure 5 Birth Prevalence of CHD Subtypes
Reported birth prevalence of the 8 most common CHD subtypes per continent. Dis
*Reported PS and TOF birth prevalence in Asia was significantly higher than in Eur
Asia was significantly lower than in Europe (p  0.001). ‡Reported TGA and AoS b
America (p  0.001) and Oceania (p  0.001). §No data on TOF and AoS birth prwhereas Chinese children have more right ventricular out-flow tract lesions. A possible explanation could be found in
genetic origin.
Interestingly, Europe had the second highest reported
total CHD birth prevalence. The difference between Eu-
rope and North America (8.2 vs. 6.9 per 1,000 live births;
p  0.001) was unexpected because the study populations
and design of the studies in these 2 continents are quite
comparable. This difference might be attributed to ethnic,
socioeconomical, and environmental differences. North
America has a relatively larger population of African-
American inhabitants and, as previously described, CHD is
less common in this population (19). Part of the difference
might also be explained by differences in healthcare and
referral systems. In the United States, as was noted in the
Baltimore-Washington Infant Study (20), referral of infants
with developmental abnormalities, such as Down syndrome
and other trisomies, for cardiac evaluation can be inhibited,
whereas these societal factors probably are of less impor-
tance in most European countries. Moreover, the fact that
we found important differences in CHD birth prevalence
according to income status also argues in favor of the fact
that lack of resources, medical insurance, screening pro-
grams, and referral systems probably lead to an underesti-
mation of the true birth prevalence.
Heterogeneity in this meta-analysis. Obviously, reported
birth CHD prevalence reflects the true CHD birth preva-
lence but also depends on the study design of the original
papers, study population selection, and diagnostic tools
used. CHD prevalence highly depends on age and gesta-
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infants (21). Furthermore, CHD prevalence highly depends
on the sensitivity and specificity of the detection method.
Differences in study population selection and inclusion and
exclusion criteria of included studies attributed to hetero-
geneity in this meta-analysis. Tests for heterogeneity
showed high heterogeneity in continents, income groups,
and time periods, but this finding can be explained by the
fact that, due to the very large sample sizes, point estimates
were very precise and SEs very small, and therefore heter-
ogeneity was expected and inevitable. We did not find bias
caused by the design (prospective or retrospective nature) or
size of included studies.
Study limitations. Even though we investigated all avail-
ble reports of total CHD and CHD subtype birth preva-
ence worldwide, checked for bias caused by study design,
nd adjusted comparisons to the era of echocardiography,
ome residual bias may be present in our estimates (e.g.,
aused by differences in quality of the papers). It remains
ifficult, as stated by others, to determine whether detected
ifferences in CHD birth prevalence are real or merely
ethodological (22). Another inevitable limitation of this
eta-analysis is that it does not really cover the entire world
opulation. Data from developing countries were scarce,
nd studies often do not include indigenous inhabitants and
ribes. Population-wide prospective birth defect registries
re necessary to determine the true birth prevalence, includ-
ng economically developing parts of the world.
onclusions
eported total CHD birth prevalence increased substan-
ially over the last century, reaching a stable estimate of 9
er 1,000 live births in the last 15 years. This corresponds to
.35 million newborns with CHD every year, representing a
ajor global health burden. Significant geographical differ-
nces were found. It remains uncertain whether detected
ifferences in CHD birth prevalence represent true or
erely methodological differences. In the future, the etiol-
gy of CHD needs to be further clarified and population-
ide prospective birth defect registries covering the entire
orld population are needed to determine the exact birth
revalence.
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